![]() |
市場調査レポート
商品コード
1540808
抗生物質市場レポート:作用機序、薬剤クラス、活性スペクトル、投与経路、エンドユーザー、地域別、2024~2032年Antibiotics Market Report by Action Mechanism, Drug Class, Spectrum of Activity, Route of Administration, End User, and Region 2024-2032 |
||||||
カスタマイズ可能
|
抗生物質市場レポート:作用機序、薬剤クラス、活性スペクトル、投与経路、エンドユーザー、地域別、2024~2032年 |
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2~3営業日
|
世界の抗生物質市場規模は2023年に514億米ドルに達しました。今後、IMARC Groupは、2024~2032年にかけて3.5%の成長率(CAGR)を示し、2032年までに707億米ドルに達すると予測しています。肺炎、結核、その他の感染症が個人の間で蔓延していること、抗菌薬耐性(AMR)の発生が増加していること、バイオテクノロジーと創薬技術の技術的進歩が市場を推進している主要要因の一部です。
抗生物質は、細菌感染を治療するために使用される医薬品の一種です。錠剤、カプセル剤、注射剤、クリーム剤、軟膏剤など、さまざまな形態で広く販売されています。細菌を死滅させるか、増殖を抑制して感染症を効果的に除去します。細菌細胞内の特定のメカニズムや構造を標的とし、その重要な機能を阻害して繁殖を阻止します。これに加えて、抗生物質は個人の免疫システムを強化する手助けをします。その結果、抗生物質は、尿路感染症(UTI)、呼吸器感染症、皮膚感染症、特定の性感染症など、様々な病気の治療に利用されています。
現在、世界中の大衆の間で多くの慢性疾患の有病率が増加していることが、市場の成長に寄与しています。さらに、世界中のオンラインショップやオフラインショップを通じて抗生物質が広く入手可能であることが、市場の成長を強化しています。これとは別に、外用抗生物質が個人の手術部位感染のリスクを最小限に抑えることから、外用抗生物質に対する需要の高まりが市場にプラスの影響を与えています。さらに、家畜の健康と福祉を守り、食の安全をサポートするために、畜産において抗生物質の使用が増加していることが、市場の成長を強化しています。これに伴い、高齢者人口における抗生物質需要の増加が市場の成長を支えています。さらに、予防医療対策に対する消費者の意識の高まりが、市場の成長を後押ししています。
感染症有病率の上昇
世界中の大衆の間で、肺炎、結核、尿路感染症(UTI)、消化管感染症、敗血症などの感染症の流行が増加しています。不衛生が細菌感染症の蔓延を助長しているため、人々はますますこれらの病気に苦しむようになっています。さらに、薬剤耐性菌の出現が抗生物質の需要を増大させています。このような感染症の治療を助ける効果的な抗生物質の需要が増加しています。抗生物質は、細菌感染を対象にし、除去するために特別に設計されています。体内の細菌を効果的に死滅させ、個人の治癒を促進します。さらに、抗生物質は患者の転帰を最適化するために医療専門家の指導の下で使用されます。
抗菌薬耐性(AMR)の増加
世界中で抗菌薬耐性(AMR)の発生が増加しており、これが抗生物質市場の推進力となっています。AMRは、細菌、ウイルス、寄生虫、真菌が進化し、それらの治療に使用される薬剤に対して耐性を持つようになることで起こります。AMRは抗生物質の有効性を低下させ、感染症の長期化・重症化、医療コストの増大、個人の高い死亡率を引き起こします。抗生物質の乱用や誤用が薬剤耐性菌の発生を助長し、従来の抗生物質が効きにくくなっています。さらに、メチシリン耐性黄色ブドウ球菌(MRSA)やカルバペネム耐性腸内細菌科細菌(CRE)のような多剤耐性株が蔓延しています。このため、これらの耐性株と闘うための新しい抗生物質や代替治療の開発が必要となっています。
抗生物質の技術的進歩
バイオテクノロジー、分子生物学、創薬技術の革新は、抗生物質開発の効率と効果の向上に役立っています。ゲノミクスと高性能スクリーニングは、潜在的な薬剤標的の同定と大規模な化合物ライブラリーのスクリーニングを可能にします。さらに、コンピューター支援型ドラッグ・デザインは、薬効の予測や抗生物質候補の最適化を可能にします。これらの技術的進歩は抗生物質探索プロセスを合理化し、従来の方法に関連する時間とコストを削減します。さらに、迅速な病原体同定や感受性試験などの診断技術の進歩は、適切な抗生物質の選択と処方を支援し、患者の転帰を向上させる。さらに、技術の進歩は、感染症や抗菌薬耐性に対処するための、より強力な新しい抗生物質の開発に役立っています。
The global antibiotics market size reached US$ 51.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 70.7 Billion by 2032, exhibiting a growth rate (CAGR) of 3.5% during 2024-2032. The growing prevalence of pneumonia, tuberculosis, and other infectious diseases among individuals, rising occurrence of antimicrobial resistance (AMR), and technological advancements in biotechnology and drug discovery techniques are some of the major factors propelling the market.
Antibiotics are a class of medications that are used to treat bacterial infections. They are widely available in various forms, such as pills, capsules, injections, creams, and ointments. They either kill bacteria or inhibit their growth to effectively eliminate infections. They target specific mechanisms or structures within bacterial cells and interfering with their vital functions and preventing their reproduction. Besides this, they assist in enhancing the immune system of individuals. As a result, antibiotics are utilized to treat various diseases, such as urinary tract infections (UTI), respiratory tract infections, skin infections, and certain sexually transmitted diseases among individuals.
At present, the increasing prevalence of numerous chronic diseases among the masses around the world is contributing to the growth of the market. Additionally, the wide availability of antibiotics through online and offline stores across the globe is strengthening the growth of the market. Apart from this, the growing demand for topical antibiotics, as they minimize the risk of surgical site infections among individuals, is positively influencing the market. Moreover, the increasing employment of antibiotics in livestock farming to safeguard animal health and welfare and support food safety is bolstering the growth of the market. In line with this, the rising demand for antibiotics among the geriatric population is supporting the growth of the market. Furthermore, the increasing consumer awareness about preventive healthcare measures is impelling the growth of the market.
Rising prevalence of infectious diseases
There is a rise in the prevalence of infectious diseases, such as pneumonia, tuberculosis, urinary tract infections (UTI), gastrointestinal infections, and sepsis, among the masses across the globe. People are increasingly suffering from these diseases due to inadequate sanitation, which contributes to the spread of bacterial infections. In addition, the emergence of drug-resistant bacteria is increasing the demand for antibiotics. There is a rise in the demand for effective antibiotics that assist in treating these infections. Antibiotics are specifically designed to target and eliminate bacterial infections. They effectively kill bacteria in the body and promote healing among individuals. Furthermore, antibiotics are used under the guidance of healthcare professionals to optimize patient outcomes.
Increasing occurrence of antimicrobial resistance (AMR)
There is a rise in the occurrence of antimicrobial resistance (AMR) across the globe, which is driving the antibiotics market. AMR occurs when bacteria, viruses, parasites, or fungi evolve and become resistant to the drugs used to treat them. It reduces the effectiveness of antibiotics and causes longer and more severe infections, increased healthcare costs, and high mortality rates among individuals. Overuse and misuse of antibiotics are contributing to the development of drug-resistant bacteria, which makes traditional antibiotics less effective. In addition, multidrug-resistant strains, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant Enterobacteriaceae (CRE), are more prevalent. This necessitates the development of new antibiotics or alternative treatments to combat these resistant strains.
Technological advancements in antibiotics
Innovations in biotechnology, molecular biology, and drug discovery techniques assist in improving the efficiency and effectiveness of antibiotic development. Genomics and high-throughput screening allow the identification of potential drug targets and the screening of large compound libraries. Moreover, computer-aided drug design enables the prediction of drug efficacy and optimizes antibiotic candidates. These technological advancements streamline the antibiotic discovery process and reduce the time and costs associated with traditional methods. Additionally, advancements in diagnostic techniques, such as rapid pathogen identification and susceptibility testing, assist in appropriate antibiotic selection and prescribing that provides enhanced patient outcomes. Furthermore, technological advancements aid in the development of new and more potent antibiotics to address infectious diseases and antimicrobial resistance.
IMARC Group provides an analysis of the key trends in each segment of the global antibiotics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on action mechanism, drug class, spectrum of activity, route of administration and end user.
Cell Wall Synthesis Inhibitors
Protein Synthesis Inhibitors
DNA Synthesis Inhibitors
RNA Synthesis Inhibitors
Mycolic Acid Inhibitors
Others
Cell wall synthesis inhibitors represent the largest market segment
The report has provided a detailed breakup and analysis of the market based on the action mechanism. This includes cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors, mycolic acid inhibitors, and others. According to the report, cell wall synthesis represented the largest segment.
Cell wall synthesis is a class of antibiotics that target the bacterial cell wall. These antibiotics interfere with the process of cell wall synthesis, which causes cell wall damage and eventual bacterial death. In addition, penicillin, cephalosporins, and carbapenems are some of the cell wall synthesis inhibitors. They work by inhibiting enzymes called penicillin-binding proteins (PBPs) that are involved in the cross-linking of peptidoglycan chains. Moreover, cell wall synthesis inhibitors are particularly effective against gram-positive bacteria due to their thicker peptidoglycan layer, which provides a greater target for disruption.
Cephalosporin
Penicillin
Fluoroquinolone
Macrolide
Carbapenem
Aminoglycoside
Others
Penicillin accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the drug class. This includes cephalosporin, penicillin, fluoroquinolone, macrolide, carbapenem, aminoglycoside, and others. According to the report, penicillin represented the largest segment.
Penicillin is a widely used class of antibiotics that belongs to the beta-lactam drug class. It works by inhibiting the synthesis of bacterial cell walls that causes cell wall damage and bacterial death. It is considered an essential medicine and is widely available as generic drugs. Apart from this, it is widely used in various healthcare settings, such as hospitals, clinics, and outpatient settings. In addition, the rising utilization of penicillin, as it is effective against various bacterial infections, is contributing to the growth of the market.
Broad-Spectrum Antibiotics
Narrow-Spectrum Antibiotics
Broad-spectrum antibiotics hold the biggest market share
The report has provided a detailed breakup and analysis of the market based on the spectrum of activity. This includes broad-spectrum antibiotics and narrow-spectrum antibiotics. According to the report, broad-spectrum antibiotics represented the largest segment.
Broad-spectrum antibiotics are a class of antibiotics that exhibit activity against a wide range of bacteria, such as gram-positive and gram-negative bacteria. In line with this, the rising adoption of broader spectrum antibiotics, as they are effective against a broader range of microorganisms compared to narrow-spectrum antibiotics, is bolstering the growth of the market. Apart from this, broad-spectrum antibiotics assist in treating infections when the causative bacteria are unknown or when the infection involves multiple bacterial species. The appropriate use of broad-spectrum antibiotics minimizes the risks of infections in the body.
Oral
Parenteral
Topical
Others
Parenteral dominates the market segment
The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral, parenteral, topical, and others. According to the report, parenteral represented the largest segment.
Parenteral antibiotics are administered via routes other than the digestive tract, such as intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes. These routes allow for direct delivery of the medication into the bloodstream or deep tissues, bypassing the gastrointestinal system. In addition, parenteral antibiotics provide rapid and predictable drug absorption and immediate therapeutic effect. They are also suitable for patients with compromised gastrointestinal function. Apart from this, it allows for accurate dosing and is particularly beneficial in cases where high drug concentrations are needed or when oral administration is not possible.
Hospitals
Specialty Clinics
Others
Hospitals accounted for the largest market share
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, specialty clinics, and others. According to the report, hospitals represented the largest segment.
Antibiotics are widely consumed in hospitals due to the increased number of patients staying in this healthcare setting. Antibiotics are administered to patients admitted with severe infections. They are also administered before surgical procedures to reduce the risk of bacterial contamination. In line with this, the rising utilization of antibiotics among individual post-surgical prophylaxis is contributing to the growth of the market. Apart from this, the increasing consumption of antibiotics due to the rising risk of multidrug-resistant infections in hospitals is supporting the growth of the market.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Asia Pacific exhibits a clear dominance, accounting for the largest antibiotics market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific represented the largest market.
Asia Pacific held the biggest market share due to the improved healthcare infrastructure. In line with this, the growing prevalence of bacterial infections to poor sanitation is contributing to the growth of the market in the Asia Pacific region. Apart from this, the increasing demand for advanced antibiotics that can effectively combat multidrug-resistant bacteria is supporting the growth of the market. Furthermore, the presence of a large number of generic drug manufacturers is propelling the growth of the market in the region.
Key players in the industry are investing in research and development (R&D) activities to discover and develop new antibiotics and focusing on antibiotic resistance, expanding the spectrum of activity, and improving the efficacy and safety profiles of antibiotics. Apart from this, they are engaging in collaboration with research institutions, academic organizations, and government bodies to leverage their expertise and address the challenges associated with antibiotic development, such as high costs and regulatory compliances. Moreover, antibiotic companies are actively promoting antibiotic stewardship programs that encourage responsible and appropriate use of antibiotics to avoid overdosage and misusage. Furthermore, companies are increasingly conducting clinical trials and adhering to safety and efficacy standards to obtain regulatory approvals for their antibiotics.
Allergan Plc (AbbVie Inc.)
Basilea Pharmaceutica AG
GlaxoSmithKline Plc
Johnson & Johnson
Melinta Therapeutics
Merck & Co. Inc.
Nabriva Therapeutics Plc
Paratek Pharmaceuticals Inc.
Pfizer Inc.
Sanofi SA
Spero Therapeutics
Tetraphase Pharmaceuticals
In 2021, Sandoz, a Novartis division, successfully completed the acquisition of GlaxoSmithKline's (GSK) cephalosporin antibiotics business. This acquisition provides them rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets to Sandoz.
In January 2020, Merck & Co. Inc. announced that U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for DIFICID(R) (fidaxomicin) for oral suspension, and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea (CDAD) in children aged six months and older.